drug
bocunebart
Phase 2updated 3mo agoby H. Lundbeck AS
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
News(1)
- Study data convince Lundbeck to push new migraine drug forwardA possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.biopharma_dive · 2mo ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that